Vimarsana
Biggest News Aggregation in the World

Page 20 - Special Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Special Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Special Access Program Today - Breaking & Trending Today

Anteris touts first successful DurAVR valve-in-valve implant - Vimarsana News

Anteris touts first successful DurAVR valve-in-valve implant

Anteris Technologies announced today that surgeons used its DurAVR heart valve for the first time in a valve-in-valve (ViV) procedure.

Space Force Seeks Input on Cloud-Based Tech for Mission Planning, Remote System Management - Vimarsana News

Space Force Seeks Input on Cloud-Based Tech for Mission Planning, Remote System Management

Looking for the latest Government Contracting News? Check out our story: Space Force Seeks Input on Cloud-Based Tech for Mission Planning, Remote System

Magic mushroom dispensary in Windsor refuses to back down, fights for legalization - Vimarsana News

Magic mushroom dispensary in Windsor refuses to back down, fights for legalization

FunGuyz sells magic mushrooms out of their storefront which has already been raided by police once. 'We just hope that having these stores [open] will draw some attention to the topic of psilocybin and the problems that are involved in accessing psilocybin,' said store co-owner

Leave Trump Alone - The American Conservative - Vimarsana News

Leave Trump Alone - The American Conservative

Because it doesn't matter.

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome - Anavex Life Sciences (NASDAQ:AVXL) - Vimarsana News

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome - Anavex Life Sciences (NASDAQ:AVXL)

Health Canada Special Access Program (SAP) Authorizes ANAVEX®2-73 (blarcamesine) for patients after successful completion of Open-Label Extension (OLE) study Granting of requests are also ongoing in United Kingdom